Comparison of effects of intra‐articular diclofenac etalhyaluronate and hyaluronic acid in a monoiodoacetate rat osteoarthritis model
Journal of Orthopaedic Research · 2025
DOI: 10.1002/jor.26012 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Orthopaedic Research, 2025. Verfasst von Soichiro Tokeshi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedic Surgery, Graduate School of Medicine, Chiba University, Chuo-ku, Japan. Hauptthemen laut MEDLINE: Hyaluronic Acid, Diclofenac, Osteoarthritis, Knee, Anti-Inflammatory Agents, Non-Steroidal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Seikagaku Corporation.
Abstract (Originalsprache)
Diclofenac etalhyaluronate (DF‐HA) sustained diclofenac release with the effects of hyaluronic acid (HA), offering long‐term analgesia in osteoarthritis. In this study, the effects of DF‐HA on pain improvement and osteoarthritis were evaluated in a rat knee monoiodoacetate‐induced osteoarthritis model compared to HA. Eight rats per group had been injected with monoiodoacetate (2.0 mg) or saline in the right knee for 4 weeks and were injected with either DF‐HA (1.25 mg/kg; 0.5 mg), HA (0.5 mg), vehicle which was a substrate without DF‐HA (50 μL), or saline and followed for 4 weeks. Mechanical plantar skin sensitivity was assessed weekly using the von Frey assay. Osteoarthritis changes were monitored with Larsen scores via CT imaging at every 2 weeks. The articular cartilage was analyzed using OARSI scores through H&E, Safranin‐O staining at 8 weeks. The percentage of Iba‐1 positive microglia in the spinal dorsal horn and of FG + CGRP‐labeled cells among FG‐positive cells in the dorsal root ganglion were evaluated by immunohistochemical staining. TNF‐α and IL‐6 mRNA expression levels in the knee synovium were evaluated by PCR. The DF‐HA showed significantly improved pain hypersensitivity compared with the HA at 6–8 weeks. The percentage of Iba‐1‐positive microglia was significantly lower than that in the vehicle and the percentage of FG + CGRP/FG was significantly lower than that in the HA. OARSI scores did not differ among treatment groups, Larsen scores indicated lower in the DF‐HA than in the vehicle. DF‐HA was as effective as HA in joint protection and significantly improved inflammatory pain compared to HA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopedic Surgery, Graduate School of Medicine, Chiba University, Chuo-ku, Japan.
- Department of Bioenvironmental Medicine, Graduate School of Medicine, Chiba University, Chuo‑ku, Japan.
- Medical Affairs, Seikagaku Corporation, Chiyoda-ku, Japan.
- Center for Frontier Medical Engineering, Chiba University, Inage‑ku, Japan.
ORCID-Profile: Soichiro Tokeshi, Miyako Suzuki-Narita, Ikuko Tajiri, Kazuhide Inage, Jun Takeuchi, Takahito Arai, Yuya Kawarai, Seiji Ohtori, Sumihisa Orita
Förderung
- Seikagaku Corporation
Zitieren
APA
Tokeshi, S., Suzuki-Narita, M., Tajiri, I., Inage, K., Takeuchi, J., Arai, T., Kawarai, Y., Terakawa, H., Ohtori, S., & Orita, S. (2025). Comparison of effects of intra‐articular diclofenac etalhyaluronate and hyaluronic acid in a monoiodoacetate rat osteoarthritis model. Journal of Orthopaedic Research. https://doi.org/10.1002/jor.26012
Vancouver
Tokeshi S, Suzuki-Narita M, Tajiri I, Inage K, Takeuchi J, Arai T, et al. Comparison of effects of intra‐articular diclofenac etalhyaluronate and hyaluronic acid in a monoiodoacetate rat osteoarthritis model. Journal of Orthopaedic Research. 2025. doi:10.1002/jor.26012
BibTeX
@article{Tokeshi2025,
author = {Tokeshi, Soichiro and Suzuki-Narita, Miyako and Tajiri, Ikuko and Inage, Kazuhide and Takeuchi, Jun and Arai, Takahito and Kawarai, Yuya and Terakawa, Hiroakira and Ohtori, Seiji and Orita, Sumihisa},
title = {Comparison of effects of intra‐articular diclofenac etalhyaluronate and hyaluronic acid in a monoiodoacetate rat osteoarthritis model},
journal = {Journal of Orthopaedic Research},
year = {2025},
doi = {10.1002/jor.26012}
}
EUVIMED